These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29317774)

  • 1. Pancreatic cancer in 2017: Rebooting pancreatic cancer knowledge and treatment options.
    Semaan A; Maitra A
    Nat Rev Gastroenterol Hepatol; 2018 Feb; 15(2):76-78. PubMed ID: 29317774
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetics and Biology of Pancreatic Ductal Adenocarcinoma.
    Dunne RF; Hezel AF
    Hematol Oncol Clin North Am; 2015 Aug; 29(4):595-608. PubMed ID: 26226899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of predictive markers in oncology: are phase 3 trials always required?
    Markman M
    Oncology; 2011; 81(1):1-2. PubMed ID: 21894048
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Pancreatic Ductal Adenocarcinoma Arising From Atypical Flat Lesions.
    Franklin O; Öman M; Wanders A
    Pancreas; 2020 Aug; 49(7):e60-e61. PubMed ID: 32658071
    [No Abstract]   [Full Text] [Related]  

  • 6. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resection of multiple invasive pancreatic ductal adenocarcinomas: A diagnostic dilemma distinguishing multicentric carcinogenesis from intrapancreatic metastasis.
    Ohike N; Norose T; Takano Y; Niiya F; Nagahama M; Matsuo K; Tanaka K; Furukawa T
    Pathol Int; 2020 Aug; 70(8):588-590. PubMed ID: 32515154
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined targeting of TGF-β, EGFR and HER2 suppresses lymphangiogenesis and metastasis in a pancreatic cancer model.
    Gore J; Imasuen-Williams IE; Conteh AM; Craven KE; Cheng M; Korc M
    Cancer Lett; 2016 Aug; 379(1):143-53. PubMed ID: 27267807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Cancer: A Review.
    Yabar CS; Winter JM
    Gastroenterol Clin North Am; 2016 Sep; 45(3):429-45. PubMed ID: 27546841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives.
    Grützmann R; Saeger HD; Lüttges J; Schackert HK; Kalthoff H; Klöppel G; Pilarsky C
    Int J Colorectal Dis; 2004 Sep; 19(5):401-13. PubMed ID: 14745573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy: Targeting mitochondria in pancreatic cancer.
    Errico A
    Nat Rev Clin Oncol; 2014 Oct; 11(10):562. PubMed ID: 25155173
    [No Abstract]   [Full Text] [Related]  

  • 13. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic strategy for intractable pancreatic cancer and its fundamental research.
    Cho K; Ishiwata T; Naito Z; Uchida E
    J Nippon Med Sch; 2010 Feb; 77(1):62-3. PubMed ID: 20154464
    [No Abstract]   [Full Text] [Related]  

  • 15. Engineered KRAS G12D-Reactive T Cells Show Promise in Pancreatic Cancer.
    Cancer Discov; 2022 Aug; 12(8):1833. PubMed ID: 35686834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics of pancreatic ductal adenocarcinoma.
    Pilarsky C; Grutzmann R
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K-Ras mutation detection in liquid biopsy and tumor tissue as prognostic biomarker in patients with pancreatic cancer: a systematic review with meta-analysis.
    Li T; Zheng Y; Sun H; Zhuang R; Liu J; Liu T; Cai W
    Med Oncol; 2016 Jul; 33(7):61. PubMed ID: 27225938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
    Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
    Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.